For the Inventor, By the Inventor

Enter assignee name

Daejeon, South Korea

Alteogen, Inc.

USPTO Granted Patents = 14

EPO Patents = 8

Forward Citations = 31

Loading Chart...

Loading Chart...

41 inventors (with patents filed for the assignee):

Soon Jae Park (13 out of 14 patents)

Hye-Shin Chung (9 out of 9 patents)

Sunbae Lee (4 out of 4 patents)

4. Minsoo Byun (4 out of 4 patents)

5. Sang Mee Lee (3 out of 3 patents)

6. Hye Shin Chung (2 out of 2 patents)

7. Jeong Soo Cho (2 out of 2 patents)

8. Yong Mo Kim (2 out of 2 patents)

9. Ji-Sun Kim (2 out of 4 patents)

10. Jin Hwan Kim (2 out of 3 patents)

11. Hyung-Nam Song (2 out of 2 patents)

12. Sang Hoon Yun (2 out of 2 patents)

13. Sun-Ah You (2 out of 2 patents)

14. Sun Ah You (1 out of 1 patent)

15. Chi Hye Park (1 out of 3 patents)

14 patents: Sort by Forward Citations

1. 12371683 - Hyaluronidase variants and pharmaceutical composition comprising the same (2025-07-29),

2. 12221638 - Method for producing recombinant hyaluronidase (2025-02-11),

3. 12090210 - Antibody-drug conjugate comprising modified antibody (2024-09-17),

4. 11981719 - Growth hormone receptor antagonists and fusion proteins thereof (2024-05-14),

5. 11866492 - Antibody specifically binding to FOLR1 and uses thereof (2024-01-09),

6. 11414476 - Method for producing fusion protein having IgG Fc domain (2022-08-16),

7. 11235065 - Antibody-drug conjugate comprising modified antibody (2022-02-01),

8. 9982032 - Stable liquid formulation of fusion protein with IgG Fc domain (2018-05-29),

9. 9902753 - Method of purifying a long-acting human growth hormone (2018-02-27),

10. 9821059 - Composition for stabilizing protein and pharmaceutical formulation comprising the same (2017-11-21),

11. 9814782 - Modified antibody in which motif comprising cysteine residue is bound, modified antibody-drug conjugate comprising the modified antibody, and production method for same (2017-11-14),

12. 9474803 - Composition for stabilizing fusion protein in which protein and FC domain are fused (2016-10-25),

13. 9051395 - Alpha-1 antitrypsin variant, preparation method thereof and use thereof (2015-06-09),

14. 9012606 - In vivo half life increased fusion protein or peptide maintained by sustained in vivo release, and method for increasng in vivo half-life using same (2015-04-21),

Alteogen, Inc. is a leading biopharmaceutical company focused on the development of innovative antibody-based therapeutics for the treatment of cancer and other diseases. With a strong emphasis on research and development, Alteogen is dedicated to advancing the field of biotechnology and improving patient outcomes. Through strategic partnerships and collaborations, Alteogen aims to bring novel therapies to market that address unmet medical needs and improve quality of life for patients worldwide.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

14 Patents

#43 in Daejeon

#777 in South Korea

#40,937 in the World

Daejeon, South Korea

Alteogen, Inc.

Forward Citations = 31

41 inventors:

Soon Jae Park (13 out of 14 patents)

Hye-Shin Chung (9 out of 9 patents)

Sunbae Lee (4 out of 4 patents)

4. Minsoo Byun (4 out of 4 patents)

5. Sang Mee Lee (3 out of 3 patents)

Please report any incorrect information to support@idiyas.com

Loading…